Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

83
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
83
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

609
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
609
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

67
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
67
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

58
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
58
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

2.1K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.1K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

170
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
170

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Program Directors Survey on the Impact of the COVID-19 Pandemic on Cardiology Fellowship Training.

JACC. Advances·2024
Same author

Preventive Cardiology in High-Risk Adolescents and Young Adults: Is the Current Training Sufficient?

JACC. Advances·2024
Same author

Depressive symptoms are associated with clinical outcomes in heart failure with reduced ejection fraction.

ESC heart failure·2024
Same author

Association of Depression Symptoms and Biomarkers of Risk on Clinical Outcomes in HFrEF.

medRxiv : the preprint server for health sciences·2023
Same author

In-Person vs Virtual Interview Format for Fellowships in Cardiovascular Disease: A Nationwide Survey of Fellows-in-Training.

Journal of the American College of Cardiology·2023
Same author

Unexpected case of chagas disease reactivation in endomyocardial biopsy for evaluation of cardiac allograft rejection.

Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology·2021
Same journal

Skin Cancer: Management of Cutaneous Melanoma.

FP essentials·2026
Same journal

Skin Cancer: Management of Actinic Keratoses and Keratinocyte Carcinomas.

FP essentials·2026
Same journal

Skin Cancer: Diagnosis.

FP essentials·2026
Same journal

Skin Cancer: Screening and Prevention.

FP essentials·2026
Same journal

Skin Cancer.

FP essentials·2026
Same journal

Obesity Management: Surgical Interventions.

FP essentials·2026
See all related articles

Related Experiment Video

Updated: Oct 28, 2025

Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

24.9K

Heart Failure: Advanced Refractory Heart Failure.

Lisa J Rose-Jones1

  • 1Division of Cardiology at Department of Medicine at University of North Carolina at Chapel Hill School of Medicine, 160 Dental Circle, Chapel Hill, NC 27599-7075.

FP Essentials
|July 15, 2021
PubMed
Summary
This summary is machine-generated.

Recognizing refractory heart failure (HF) is crucial for timely advanced therapy evaluation. Early palliative care referral improves quality of life for end-stage HF patients.

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.6K
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

328

Related Experiment Videos

Last Updated: Oct 28, 2025

Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

24.9K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.6K
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

328

Area of Science:

  • Cardiology
  • Internal Medicine
  • Palliative Care

Background:

  • End-stage heart failure (HF) presents a poor prognosis despite optimal medical therapy.
  • Persistent symptoms indicate advanced disease, necessitating recognition for appropriate management.
  • Identifying refractory HF is key for timely evaluation of advanced treatment options.

Purpose of the Study:

  • To highlight the importance of recognizing refractory heart failure (HF) signs and symptoms.
  • To emphasize the need for timely evaluation for advanced therapies like left ventricular assist devices and heart transplantation.
  • To underscore the role of palliative care and hospice in managing end-stage HF.

Main Methods:

  • This is a review and discussion of current clinical understanding and management strategies for end-stage heart failure.
  • Focuses on clinical recognition of refractory HF and pathways for advanced therapy referral.
  • Integrates palliative care and hospice considerations into the management framework.

Main Results:

  • Physicians must identify patients with refractory HF to facilitate timely evaluation for advanced therapies.
  • Early referral for advanced therapy evaluation can prevent irreversible end-organ damage.
  • Palliative care referral is recommended for all end-stage HF patients to manage symptoms and enhance quality of life.

Conclusions:

  • Timely recognition and referral are critical for patients with end-stage heart failure (HF).
  • Advanced therapies (LVAD, transplantation) are options for select patients, requiring prompt evaluation.
  • Palliative care and hospice discussions are essential components of comprehensive end-stage HF management.